Suggested remit: To appraise the clinical and cost effectiveness of denecimig (Mim8) within its marketing authorisation for preventing bleeding episodes in haemophilia A in people 1 year and over.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6400
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6400:
- 10 December 2025 - 15 January 2026
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 December 2025 | Awaiting development. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early March 2026 when we will write to you about how you can get involved. |
| 10 December 2025 | In progress. Scoping commencing |
| 31 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual